Trials / Approved For Marketing
Approved For MarketingNCT02065765
International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
An International Single-Arm Protocol to Provide Expanded Access to Ramucirumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression After Prior Fluoropyrimidine and/or Platinum-Containing Chemotherapy
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the compassionate use program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ramucirumab | Administered intravenously (IV) |
Timeline
- First posted
- 2014-02-19
- Last updated
- 2025-01-09
Locations
44 sites across 5 countries: Austria, Germany, Greece, Netherlands, South Korea
Source: ClinicalTrials.gov record NCT02065765. Inclusion in this directory is not an endorsement.